Breast cancer risk reduction: Clinical Practice Guidelines in Oncology™

Therese B. Bevers, Deborah K. Armstrong, Banu Arun, Robert W. Carlson, Kenneth H. Cowan, Mary B. Daly, Irvin Fleming, Judy E. Garber, Mary Gemignani, William J. Gradishar, Helen Krontiras, Swati Kulkarni, Christine Laronga, Tom Lawton, Loretta Loftus, Deborah J. MacDonald, Martin C. Mahoney, Sofia D. Merajver, Victoria Seewaldt, Rena V. SellinCharles L. Shapiro, Eva Singletary, John H. Ward

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Breast cancer risk assessment provides a means of identifying healthy women at increased risk for future development of this disease. However, many of the risk factors for breast cancer are not modifiable. The demonstration that use of tamoxifen or raloxifene for 5 years decreases the future risk for breast cancer by nearly 50% provides an opportunity for a risk reduction intervention. However, the risks and benefits associated with use of tamoxifen or raloxifene for an individual woman should be evaluated and discussed with patients as part of a shared decision-making process. Women taking a risk reduction agent must be closely monitored for potential side effects associated with use of these agents. In special circumstances, such as in carriers of a BRCA1/2 mutation, for whom the risk for breast cancer is very high, the performance of a bilateral mastectomy or bilateral salpingo-oophorectomy may be considered for breast cancer risk reduction. Women considering either surgery should undergo multidisciplinary consultations before surgery to become well informed about all treatment alternatives, the risks and benefits of risk reduction surgery, and, in the case of bilateral mastectomy, the various reconstruction options available. The panel strongly encourages women and health care providers to participate in clinical trials to test new strategies to decrease the risk for breast cancer. Only through the accumulated experience gained from prospective and well-designed clinical trials will additional advances in the reduction of breast cancer risk be realized.

Original languageEnglish (US)
Pages (from-to)676-701
Number of pages26
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume5
Issue number8
StatePublished - Sep 2007

Keywords

  • BCRA1
  • BCRA2
  • Breast carcinoma
  • LCIS
  • NCCN Clinical Practice Guidelines
  • Prophylactic mastectomy
  • Raloxifene
  • Risk assessment
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Breast cancer risk reduction: Clinical Practice Guidelines in Oncology™'. Together they form a unique fingerprint.

Cite this